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ABSTRACT
Background
Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood
vessels leading to acute painful crises and other complications. Recent research has focused on therapies to rehydrate the sickled cells
by reducing the loss of water and ions from them. Little is known about the effectiveness and safety of such drugs.
Objectives
To assess the relative risks and benefits of drugs to rehydrate sickled red blood cells.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Haemoglobinopathies Trials Register.
Last search of the Group’s Trials Register: 25 October 2011.
Selection criteria
Randomized or quasi-randomized controlled trials of drugs to rehydrate sickled red blood cells compared to placebo or an alternative
treatment.
Data collection and analysis
Both authors independently selected studies for inclusion, assessed study quality and extracted data.
Main results
Of the 51 studies identified, three met the inclusion criteria. The first study tested the effectiveness of zinc sulphate to prevent sickle
cell-related crises in a total of 145 participants and showed a significant reduction in painful crises over one and a half years, mean
difference -2.83 (95% confidence interval -3.51 to -2.15). However, analysis was restricted due to limited statistical data. Changes to
red cell parameters and blood counts were inconsistent. No serious adverse events were noted in the study.
The second study was a Phase II dose-finding study of senicapoc (a Gardos channel blocker) compared to placebo. Compared to the
placebo group the high dose senicapoc showed significant improvement in change in hemoglobin level, number and proportion of
Drugs for preventing red blood cell dehydration in people with sickle cell disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

dense red blood cells, red blood cell count and indices and hematocrit. The results with low-dose senicapoc were similar to the highdose senicapoc group but of lesser magnitude. There was no difference in the frequency of painful crises between the three groups. A
subsequent Phase III study of senicapoc was terminated early since there was no difference observed between the treatment and control
groups in the primary end point of painful crises.
Authors’ conclusions
While the results of zinc for reducing sickle-related crises are encouraging, larger and longer-term multicenter studies are needed to
evaluate the effectiveness of this therapy for people with sickle cell disease.
While the Phase II and the prematurely terminated phase III studies of senicapoc showed that the drug improved red cell survival
(depending on dose), this did not lead to fewer painful crises.

PLAIN LANGUAGE SUMMARY
Drugs that aim to reduce the loss of water from red blood cells in people with sickle cell disease
Sickle cell disease is an inherited condition that causes red blood cells to become sickle shaped when they lose water. This leads to a
high risk of the blood vessels becoming blocked. Such blockages can cause pain, stroke and damage to organs. Recent therapies aim
to stop the cells becoming sickle shaped by preventing them losing water. This review included three studies, one with zinc sulphate
and two with senicapoc. The study with zinc sulphate showed that this drug may be able to reduce the number of sickle cell crises
without causing toxic effects. There were 145 participants in this study and results showed a significant reduction in the total number
of serious sickle-related crises over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15). However,
our analysis was limited since not all data were reported. Changes to red cell measurements and blood counts were not consistent. No
serious adverse events were noted in the study. The two studies with senicapoc demonstrated that this drug increases the red blood
survival and has a role in the prevention on red blood cell dehydration in people with sickle cell disease. The higher dose of the drug
was more effective compared to the lower dose. But these changes in the red blood cells did not translate into positive clinical outcomes
in terms of reduction in the number of sickle cell crises. Senicapoc had a favourable safety profile. More longer-term research is needed
on these drugs and others that might prevent water loss in red blood cells.

BACKGROUND
Description of the condition
Sickle cell disease is caused by the inheritance from both parents
of a mutation in the beta-globin gene. The different types of the
disease (e.g. SS, SC, SβThal) are caused by inheritance of different
altered beta-globin genes, and this can be diagnosed with blood
tests or genetic testing. It is so named because the red blood cells
(erythrocytes) become distorted into unusual shapes when they
give up the oxygen they carry, due to polymerisation of the abnormal hemoglobin within. This is accelerated by a cycle of red
blood cell dehydration, which increases intracellular concentration of the sickle hemoglobin and hence polymerisation. One of
the distinguishing features of sickle cell anemia is the presence of
these dense, dehydrated red cells, which are easily destroyed and
can mesh together to block blood vessels (vaso-occlusion).

The disease is characterised by episodes of anemia, vaso-occlusive
crises and organ damage, with symptoms which are unpredictable
and differ between individuals (Serjeant 1992). It is most prevalent in populations originating from sub-Saharan Africa and parts
of India; although population movement has made it a worldwide problem, with approximately 60,000 African-American and
10,000 British people with the disease (Davies 1997; Hickman
1999). Clinical management centers around prophylaxis against
infection, pain relief, hydration and periodic blood transfusion
in many people to reduce the concentration of sickle cells in the
blood stream. However, most treatment is symptomatic and, as
a result, despite vastly improving care services, many people with
the disease still die in childhood due to sudden bouts of infection, stroke, acute chest syndrome or splenic sequestration (Leikin
1989). Clearly preventative measures would be preferable.
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How the intervention might work
In an attempt to prevent the increased concentration of sickle
hemoglobin (which causes polymerisation and deformation of the
red blood cell), recent research has begun to target the physiological process leading to dehydration of the erythrocyte for therapeutic potential. Red cells are thought to undergo dehydration via
two kinetically distinct pathways, a “fast track” process in reticulocytes (immature red blood cells), and a slow process involving mature erythrocytes. Dehydration via either pathway is due to
the water loss accompanying primary loss from the cell of potassium and chloride ions. The major routes involved in sickle cell
dehydration are the calcium-activated potassium channel (Gardos
channel) operating in parallel with the conductive chloride pathway and the electroneutral potassium-chloride co-transporter(s)
(Brugnara 1995). Potential therapeutic approaches involve the use
of drugs that reduce sickle cell dehydration via a block of these
mechanisms.
The first route, and perhaps the most promising for therapy, is
the Gardos channel. Upon deoxygenation of the sickle cell, potassium and water loss are induced as free intracellular calcium levels rise, possibly due to increased membrane permeability for calcium. The Gardos channel may also be positively modulated by
vaso-active molecules such as endothelins (Rivera 2000). Studies
both in a mouse model for sickle cell disease (SAD mouse) and in
humans have shown that this channel can be selectively inhibited
by a group of drugs known as the imidazole antimycotics, including the anti-fungal agent clotrimazole (Brugnara 1993; Brugnara
1996; de Franceschi 1994) and a related compound Senicapoc
(ICA-17043) (Stocker 2000). Blocking of the Gardos channel resulted in increased potassium content and improved hydration
of erythrocytes. Senicapoc (bis(4-fluorophenyl)phenyl acetamide)
is a selective and potent blocker of the Gardos channel (Stocker
2003). Dimethyl adipimate may also have an anti-sickling role via
the Gardos channel (Gibson 2000).
The role of the chloride conductance or exchange system in sickle
cell dehydration has also been recently explored. In vitro, loss of
potassium from deoxygenated human sickle cells could be limited
by the reversible anion conductance inhibitor NS1652 (Bennekou
2000). Further, the related compound, NS3623 (Bennekou 2001),
which has a greater half-life in vivo, improved hydration in the
SAD mouse.
Potassium-chloride co-transport occurs via a different membrane
protein, which is activated by acidity within the cell allowing loss
of potassium and water. This is seen almost exclusively in reticulocytes. No drugs have been found to be useful in inhibiting the
transporter, but it has been shown that divalent cations, such as
magnesium ions (Brugnara 1987), can block the pathway, again
protecting against dehydration. Magnesium preparations are currently marketed for treatment of constipation, boils, recurrence
of seizures in eclampsia, renal failure and are recommended for
emergency treatment of serious arrhythmias. Magnesium pidolate

has been investigated in combination with hydroxyurea in a Phase
I trial (Hankins 2008).
Other strategies have also been suggested for reducing sickle red
cell dehydration. These include a transmembrane sodium-potassium pump mechanism which is partly responsible for increased
ion permeability on deoxygenation. While this is thought to be a
minor contributor to dehydration, dipyridamole has been shown
to be a selective inhibitor of passive ion transfer and there is rationale, including the known effects on platelet and endothelial
cell function, for testing its efficacy in sickle cell disease. Oxidative damage to the cell membrane, which can occur in sickle cell
disease due to abnormal iron deposits, increases loss of potassium
and water contributing to red cell dehydration (Brugnara 1995).
Oral iron chelators may help in this case, and antioxidants could
also be useful (Gibson 1998). Nitric oxide, an endogenous compound which is thought to be an important regulator of smooth
muscle tone and vasodilatation, is reduced in people with sickle
cell disease (Qureshi 2000). Preliminary studies in SAD mice have
shown that it can reduce red cell dehydration (Adrie 2000), and
oral supplementation with arginine, an amino acid which releases
nitric oxide, (5% by weight) also induces a decrease in red cell density (Romero 2000), via Gardos channel activity (Romero 2002).
Hydroxyurea, an anti-cancer compound proven to reduce sicklerelated events (Charache 1995; Jones 2001), improves the hydration status of sickle red blood cells (Ballas 1989), although it is not
clear whether this is a direct effect, or a consequence of increased
levels of fetal hemoglobin (HbF).
In Brazil a local plant, Pfaffia paniculata, has been anecdotally
reported to ameliorate clinical symptoms of sickle cell disease. The
plant possibly contains a naturally occurring compound, which
acts as a sodium ionophore. ’In vitro’ studies have shown increased
erythrocyte deformability and sodium content of sickle red cells
when treated with it, thus potentially rehydrating sickle cells (
Ballas 2000).
Piracetam (2-oxo-1-pyrrolidine acetamide), a derivative of the
neurotransmitter gamma-aminobutyric acid (GABA), works primarily in neurotransmission, but appears to have a beneficial effect
on red cell rheology and thus able to reduce vaso-occlusive crises
in people with sickle cell disease. The exact mechanism of this remains unclear. It does not appear to inhibit the Gardos channel as
previously reported (Gini 1987; Stone 1988; Stuart 1990; Stuart
1992). The use of piracetam for reducing the incidence of painful
sickle cell disease crises is the subject of another Cochrane Review
(Al Hajeri 2007).

Why it is important to do this review
All of these potential therapies look promising for reducing dehydration of red blood cells, and therefore ameliorating the symptoms of sickle cell disease. This review aims to bring together clinical trials in this area to establish the clinical value of this pharmaceutical approach.
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OBJECTIVES
To determine whether pharmaceutical therapies designed to prevent red cell dehydration in sickle cell disease:
1. reduce mortality;
2. reduce sickle cell vaso-occlusive crises including episodes of
pain and stroke;
3. reduce other complications associated with sickle cell
disease e.g. acute chest syndrome, infection, anemia, splenic
sequestration, organ damage;
4. are associated with unacceptable adverse events.

METHODS

Types of outcome measures
While the interventions should, by definition, decrease dense sickled cells by reducing erythrocyte dehydration, such biochemical
parameters were examined separately from clinical outcomes, to
determine the effectiveness of the interventions in clinical practice. However, the hematological outcomes may also provide an
indication of the efficacy, and potential effectiveness, of treatment,
so these were also analyzed.

Primary outcomes

1. Number of deaths
2. Number of sickle pain crises (requirement for opiate
treatment or self reported patient scales)
3. Number of serious complications of sickle cell disease
including stroke, acute chest syndrome and acute splenic
sequestration

Secondary outcomes

Criteria for considering studies for this review

Types of studies
Randomized or quasi-randomized trials. Trials in which quasirandomized methods, such as alternation, are used were included
if there was sufficient evidence that the treatment and control
groups were similar at baseline.

1. Red cell dehydration (proportion of dense cells, mean
corpuscular hemoglobin concentration (MCHC), mean
corpuscular volume (MCV))
2. Full blood count including hemoglobin, white blood cell
and platelet counts, sickle cell hemoglobin (HbS) and foetal
hemoglobin (HbF) level
3. Quality of life: days off work or school, hospitalisations,
mobility, etc.
4. Number of other sickle-related events, including priapism,
leg ulceration

Types of participants

Other outcomes

People with known sickle cell disease (SS, SC, Sβ+ and Sβ0,
proven by electrophoresis and sickle solubility test, with family
studies or DNA tests as appropriate) of all ages and both sexes, in
any setting.

1. Any reported adverse effects or toxicity of drugs were
recorded

Search methods for identification of studies
Types of interventions
Pharmaceutical therapies designed to reduce red cell dehydration
to prevent vaso-occlusive events in sickle cell disease compared
to comparator interventions. Studies which included anti-sickling
drugs for which the exact mechanism of action is not known were
considered if there was some evidence that they act via the red
blood cell membrane to prevent sickling. Piracetam was excluded
since there is insufficient evidence that it acts primarily via the
red cell membrane to improve red cell rheology. Hydroxyurea was
excluded as the primary mechanism for this drug is through increasing foetal hemoglobin. Studies in which the intervention was
given only to treat an existing sickle-related event were excluded.

Electronic searches
Relevant studies were identified from the Cystic Fibrosis & Genetic
Disorders Review Group’s Haemoglobinopathies Trials Register
using the terms: sickle cell AND (dehydration OR anti-sickling
OR crises).
The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of The Cochrane Library)
and quarterly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences:
the European Haematology Association conference; the American
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Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research
Council Meetings; and the National Sickle Cell Disease Program
Annual Meeting. For full details of all searching activities for the
register, please see the relevant section of the Cystic Fibrosis and
Genetic Disorders Group Module.
Date of the most recent search of the Group’s
Haemoglobinopathies Trials Register: 25 October 2011.

odds of an outcome among treatment allocated participants to the
corresponding odds among controls).

Unit of analysis issues
Cross-over trials will only be included in future versions of this
review if we consider there to be a sufficient washout period between the treatment arms. We will analyze any data from such trials according to methods described by Elbourne (Elbourne 2002).

Searching other resources
The bibliographic references of all retrieved literature were reviewed for additional reports of studies.

Data collection and analysis

Selection of studies
Two authors independently applied the inclusion criteria in order
to select studies for inclusion in the review. If disagreement arose
on the suitability of a study for inclusion in the review, the authors
reached consensus by discussion.

Data extraction and management
Two authors independently extracted the data. Each author, using
standard data acquisition forms, independently extracted data. If
disagreement arose on the study quality, the authors reached a
consensus by discussion.
We planned to collect data at monthly time-frames. However, if
data were reported at other time periods we planned to consider
examining these as well.

Assessment of risk of bias in included studies
Two authors assessed the risk of bias of each study. In particular,
authors examined details of the randomization method, allocation
concealment, whether the study was blinded, whether intentionto-treat analyses were possible from the available data and if the
number of participants lost to follow up or subsequently excluded
from the study was recorded.

Dealing with missing data
We sought full reports from authors where studies have been published in abstract form, presented at meetings or reported to the
co-authors. Where information was missing or unclear, we contacted the primary investigator.
In order to allow an intention-to-treat analysis, we grouped data
by allocated treatment groups, irrespective of later exclusion (regardless of cause) or loss to follow up.

Assessment of heterogeneity
We will test for heterogeneity between studies using a standard
chi-squared test and I2 statistic (Higgins 2003). We will use the
following ranges to describe heterogeneity:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.

Assessment of reporting biases
Comprehensive searches were done by both the authors to minimize publication and reporting biases. We compared the ’Methods’ section of the full published paper to the ’Results’ section to
ensure that all outcomes which were measured, were reported.

Data synthesis
We have used fixed-effect analysis with the data we have presented.
If there is a high or moderate degree of heterogeneity between
studies included in any future updates, we will consider using a
random-effects analysis.

Measures of treatment effect

Subgroup analysis and investigation of heterogeneity

We recorded dichotomous outcomes e.g. life or death, as present
or absent, whilst recording continuous data such as organ function tests as either mean change from baseline for each group or
mean post treatment values and standard deviation (SD) for each
group. We aimed to calculate a pooled estimate of the treatment
effect for each outcome across studies, (for binary outcomes the

If we find heterogeneity between studies, examination of subgroups, such as age of participants, type of sickle cell disease or
ethnicity, may help to explain the reasons for this.
For future updates, where appropriate, we plan to perform subgroup analysis of different drugs or combinations of drugs to examine their relative risks and benefits.
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Sensitivity analysis
If we include a sufficient number of studies where quasi-randomization methods are used, we will analyze this group separately.

RESULTS

Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Fifty-one studies of anti-sickling agents were identified from the
searches. Three studies were included within the review (Ataga
2008; Ataga 2011; Gupta 1995).
Included studies

Trial Design

All three studies were described as double-blind, randomized
placebo-controlled studies (Ataga 2008; Ataga 2011; Gupta
1995). The Phase II Ataga study was a dose-finding study which
compared a 10 mg dose of senicapoc to a 6 mg dose of senicapoc
or to placebo. The trial was multicenter (19 medical centers) in
the United States of America (Ataga 2008). The study treated participants for 12 weeks (Ataga 2008).The recent senicapoc trial was
a Phase III trial was conducted across 75 centers in 6 countries
(Ataga 2011). The patients were randomized to senicapoc (20 mg
twice daily as a loading dose for 4 days followed by 10 mg daily)
or placebo in a 1:1 fashion. The treatment phase consisted of 52
weeks followed by a follow-up period of 8 weeks (Ataga 2011).
The Gupta trial was from a single center in India (Gupta 1995).
The Gupta study lasted for one and a half years; participants were
seen weekly but data were analysed at the end of the follow-up
period (Gupta 1995).
Participants

There were 524 participants with sickle cell disease included in the
review. The Phase II senicapoc study randomized 90 participants
aged between 18 to 60 years (Ataga 2008). The Phase III senicapoc
study randomized 297 participants between the ages of 16 and
65 years, but only the 289 patients in the modified intent-to-treat
group (participants who received at least one dose of the drug)
were included in this review (Ataga 2011). In the remaining study,
Gupta randomized 145 participants aged between 12 to 27 years
(Gupta 1995).

In the Phase II senicapoc study, participants had at least one
episode of sickle cell-related painful crisis four weeks prior to the
study screening and participants taking hydroxyurea had to be on
a stable dose of the drug for at least three months prior to their
enrolment in the study (Ataga 2008). In the Phase III senicapoc
study, participants had at least two episodes of painful crisis within
the preceding 12 months that required medical attention (Ataga
2011). Patients on hydroxyurea in preceding 12 months were required to be on a stable dose of the drug prior to inclusion in the
study (Ataga 2011). Gupta excluded participants under five years
of age or those who had a history of chronic persistent infection,
evidence of organ failure, exposure to extreme temperatures or
were taking other medication (Gupta 1995).
In the Phase II senicapoc study, all the participants who received at
least one week of the drug and underwent the initial efficacy analysis were included in the modified intent-to-treat analysis. Eightyeight participants met this criteria and only two discontinued the
study before the initial efficacy analysis (Ataga 2008). In the Phase
III senicapoc study 289 patients from the initial group of 297 were
included in the modified intent-to-treat analysis based on patients
who received at least one dose of the drug (Ataga 2011). However,
in the Gupta study, 15 participants out of the original 145 subsequently dropped out or were lost to follow-up, and these were not
included in the analysis (Gupta 1995).

Interventions

The Phase II senicapoc study compared three groups: high-dose
senicapoc (single 150 mg loading dose followed by 10 mg daily
maintenance dose); or low-dose senicapoc (single 100 mg loading
dose followed by 6 mg daily maintenance dose); or placebo (Ataga
2008). The high-dose senicapoc group had 31 participants, the
low-dose senicapoc and placebo groups had 29 and 30 participants
assigned respectively. The Phase III senicapoc study stratified participants based on concomitant hydroxyurea therapy. In each of
these groups participants were randomized to receive senicapoc
(loading dose of 20 mg twice daily for four days followed by 10
mg daily) or placebo in a 1:1 fashion. Out of the 289 patients in
the modified intent-to treat analysis, there were 163 patients in
the hydroxyurea group and 126 in the non-hydroxyurea group.
The hydroxyurea group had 84 patients receiving senicapoc and
79 patients on placebo. The non-hydroxyurea group had 61 senicapoc patients and 65 in the placebo group (Ataga 2011). The
third study randomized participants to receive either zinc sulphate
(220 mg three times a day orally) or an identical placebo (Gupta
1995).

Outcomes measured

The Ataga Phase II study reported the effect of senicapoc on
hemoglobin levels, red blood cell (RBC) indices, markers of
hemolysis and painful crises. The primary end point of the study
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was the change in hemoglobin level with the secondary end points
being changes in the number and proportion on the dense red
blood cells (RBCs) and reticulocytes, lactate dehydrogenase, indirect bilirubin, RBC count, RBC indices, hematocrit and frequency
of painful crises (Ataga 2008). The primary end point in the Ataga
Phase III was the frequency of sickle cell pain crises. TIme to the
first, second and third acute painful crises was a secondary end
point of the study (Ataga 2011). The effect of the drug on markers of hemolysis, hemoglobin, hematocrit, reticulocyte count, red
blood cell count and dense erythrocytes were also measured. The
Gupta study measured the number of sickle-related crises, and the
number of days in hospital and working (or school) days lost for
each crisis (Gupta 1995).

Excluded studies
Forty-eight studies were excluded. Reasons for exclusions were a
lack of evidence that they were acting primarily on red cell dehydration pathways, or they were being used to treat a sickle-related
crisis, rather than preventing it, or the study was not randomized
(see Characteristics of excluded studies table). Studies on piracetam were excluded since there is insufficient evidence that this
drug acts primarily via the red cell membrane to improve red cell
rheology (Alvim 2005; Piracetam Study 1998).

Risk of bias in included studies

the 90 participants dropped out prior to the initial assessment and
so 88 participants were included as a part of the modified intentto-treat population. The safety analysis included all the 90 participants. A total of 10 participants did not complete the study; full
reasons for this were given in the published paper and we therefore
judged there to be a low risk of bias due to incomplete outcome
data (Ataga 2008).
The Phase III senicapoc study was terminated early due to a lack of
efficacy as determined by the unblinded Data Monitoring Committee (Ataga 2011). The reasons for the Committee’s decision
were based on the fact that there was no significant improvement
in the rate of sickle cell painful crises in patients treated with senicapoc compared to those on placebo (P = 0.38 versus P = 0.31 respectively) despite improvements in anemia and hemolysis. Moreover, comparisons of the times to first, second and third crises
between the senicapoc and placebo groups were not significantly
different. The authors suggest that the increase in Hb level caused
an increase in blood viscosity and offset the potential benefits of
senicapoc with regards to painful crises. Furthermore, due to the
early termination of the study, the duration that the drug was administered was different in the patients who stopped treatment
early. Given these facts, we have not entered any data from this
trial into the data tables and results are reported narratively.
In the zinc study, a power calculation, which assumed 40% control
event rate and 20% response, found that 130 participants were
needed. Fifteen, of the 145 participants recruited, dropped out
or were lost to follow-up, and these are not accounted for in the
study publication (Gupta 1995). We therefore judge there to be
an unclear risk of bias from reported outcome data for this study.

Allocation
All three studies were judged to have a low risk of bias for the
generation of the allocation sequence (Ataga 2008; Ataga 2011;
Gupta 1995). In both of the senicapoc studies an integrated voice
response system was used in the centralized randomization protocol (Ataga 2008; Ataga 2011). In the zinc study, New Castle
software was used to generate randomization (Gupta 1995).
Both the senicapoc studies and the zinc study did not report on
allocation concealment and so all studies were judged to have an
unclear risk of bias for this criteria (Ataga 2008; Ataga 2011; Gupta
1995).
Blinding
Both the participants and treating physicians were blinded in all
three studies and so were judged to have a low risk of bias (Ataga
2008; Ataga 2011; Gupta 1995). Additionally, Ataga reported that
the review committee were also blinded (Ataga 2008).
Incomplete outcome data
In the senicapoc Phase II study, a modified intent-to-treat population was used in the efficacy analysis (Ataga 2008). Two out of the

Selective reporting
In both the senicapoc studies and the zinc study, all outcomes
stated in ’Methods’ section were reported in the ’Results’ section
of the papers; therefore there is a low risk of bias for selective
reporting for all studies (Ataga 2008; Ataga 2011; Gupta 1995).

Other potential sources of bias
The participants in the Phase II senicapoc study were evenly
matched in terms of their baseline characteristics between the three
study arms (Ataga 2008) and this was also true for the Phase III
senicapoc study (Ataga 2011). There was no significant difference
in the mean age, sex and the hospitalizations in the year prior to
the enrolment in the study. We therefore judged both studies to
have a low risk of bias for this domain.
The zinc study gave little information regarding baseline characteristics, including disease severity and medical history of participants, making it difficult to ascertain if the groups were sufficiently
similar at the start of the study (Gupta 1995). Thus currently we
judge there to be an unclear risk of bias for this study.
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Effects of interventions

Primary outcomes

1. Number of deaths

No treatment related deaths were reported in the included studies
(Gupta 1995; Ataga 2008; Ataga 2011).

2. Number of pain crises

In the senicapoc Phase II study there were a total of 15 sickle
cell crises, with the events being distributed equally between the
placebo and the two intervention arms (five in each) (Ataga 2008).
So both the lower (6 mg) and higher doses (10 mg) of senicapoc
did not help in the reduction of painful crises compared to placebo.
The Phase III senicapoc study was terminated prematurely as it was
unlikely to meet the primary endpoint (Ataga 2011). There was
no significant difference in the rate of the sickle cell painful crises
between the senicapoc and placebo groups (0.38 versus 0.31, P =
0.054). There was no difference in the painful crises rate between
the two treatment arms in the hydroxyurea group (0.39 versus
0.33, P = 0.483) but the rate of painful crises was significantly
higher in the senicapoc group compared to the placebo group in
patients not on hydroxyurea (0.37 versus 0.29, P = 0.037) (Ataga
2011). The study included pain-only crises, acute chest syndrome,
hepatic sequestration, priapism and stroke under the primary end
point of sickle cell-related pain crises. Given that the study was
terminated prematurely, there are very few patients who completed
the treatment. The duration of the drug regimen was different
in the patients who stopped treatment. Therefore we have not
included any data from this trial in the data analysis table.
In the zinc study there were 91 vaso-occlusive crises in the intervention group, compared to 220 in the control group (Gupta
1995). This amounts to, on average, 1.40 and 3.38 painful crises
per participant in intervention and control groups respectively.
Standard deviations cannot be calculated from the data provided
in the publication, so we are attempting to contact the authors,
and hope to provide this information in a future update.

3. Number of other serious sickle-related complications

In the Phase II senicapoc study, there were two episodes of pneumonia and one episode of bronchitis in the placebo group (Ataga
2008). There was one episode of pneumonia in each of the intervention arms. There was a single episode of acute chest syndrome
in the study and it occurred in the 6 mg (low-dose) senicapoc arm.
There was one episode of aseptic necrosis of the bone in the lowdose senicapoc arm and one episode of deep venous thrombosis in
the high-dose senicapoc arm. Furthermore, there was one episode
of staphylococcal sepsis in the low-dose senicapoc group and one

urinary tract infection in the high-dose senicapoc group. The only
case of deep vein thrombosis was reported in the high-dose senicapoc group (Ataga 2008).
The Phase III senicapoc study included pain-only crises, acute
chest syndrome, hepatic sequestration, priapism and stroke under
the primary end point of sickle cell-related pain crises (Ataga
2011).
In the zinc study, altogether there were 160 episodes of sicklerelated crises in the intervention group, and 344 in the control
group (Gupta 1995). Of these, vaso-occlusive crises accounted for
59% in the intervention group and 64% in the control group,
mixed crises for 24% and 20% in the intervention and control
groups respectively, 9% and 12% were hemolytic, 1% in each
group sequestration and 1% in each group had aplastic crises.
The mean number of all sickle-related crises in the intervention
group was 2.46 (SD 1.04), compared to 5.29 (SD 2.58), in the
control group. The MD between groups was -2.83 (95% CI 3.51 to -2.15), showing a statistically significant reduction in the
participants treated with zinc (Gupta 1995).
Secondary outcomes

1. Red cell dehydration

Both the high and low doses of senicapoc resulted in a significant
decrease in the percentage of dense red blood cells compared to
the placebo (Ataga 2008). The magnitude of decrease was higher
with the 10 mg senicapoc compared to the 6 mg senicapoc. There
was a significant decrease in the MCV and mean corpuscular
hemoglobin (MCH) in the high-dose senicapoc group compared
to the placebo. The low-dose senicapoc caused a significant reduction in the MCH but not MCV when compared to the placebo.
There was no significant difference in MCHC between the two
intervention arms and the placebo arm. The biochemical markers of hemolysis like lactate dehydrogenase and indirect bilirubin
were significantly lower in the senicapoc groups compared to the
placebo group. The magnitude of the change was dependent on
the dose of senicapoc.
The findings seen in the Phase II senicapoc study were confirmed
in the Phase III study where senicapoc was compared to a placebo
(Ataga 2011).
The Gupta paper reported significant improvements in laboratory parameters of red cell dehydration (hemoglobin, reticulocyte
count, serum bilirubin and serum zinc level) in the intervention
group (Gupta 1995).
2. Full blood count

The senicapoc study demonstrated an increase in the hemoglobin
level by 0.68 gm/dl in the high-dose senicapoc group compared
to the 0.01 gm/dl increase in the placebo group (P <.001) (Ataga
2008). There was no significant change in the hemoglobin level
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when 6 mg of senicapoc was compared to the placebo. There was
significant increase in the RBC count with senicapoc compared to
the placebo in a dose-dependent manner.
Both the high and low doses of senicapoc resulted in a significant
decrease in the percentage and absolute number of reticulocytes
(Ataga 2008).
The above findings were confirmed in the Phase III senicapoc
study. There was no significant change in the HbF levels (Ataga
2011).
Gupta reported that participants in the intervention group had a
mean hemoglobin level of 7.9 g/dl compared to 6.8 g/dl in the
control group (P < 0.01) (Gupta 1995). Other outcomes were
not reported, and SDs were not given. Again, the authors will be
contacted to clarify this information.

in the low-dose senicapoc group had dyspnoea and weakness and
two in the high-dose senicapoc group had acute chest syndrome
and painful crises. Diarrhea and nausea of mild to moderate intensity were more common in the senicapoc groups compared to
the placebo group.
Nausea and urinary tract infections were significantly higher in
the senicapoc-treated patients compared to placebo in the Phase
III senicapoc study. All other adverse events were similar between
the two treatment groups (Ataga 2011).
The Gupta study states that zinc was well-tolerated with no significant toxicity throughout the study, although it was unclear which
potential toxic effects were monitored (Gupta 1995).

3. Quality of life measures

DISCUSSION

These measures were not assessed in the Phase II study of senicapoc
(Ataga 2008).
In the Phase III senicapoc study there was no difference in the
FACIT-Fatigue scores between the two treatment arms irrespective
of the hydroxyurea stratification. Similarly, there was no difference
in the number of patients transfused, the number of transfusions
or units per patient. The patients on senicapoc spent more days
in the hospital compared to those on placebo (Ataga 2011).
Gupta reported the mean length of hospital stay per crisis in the
intervention and control groups respectively was 4.3 and 3.9 days,
MD 0.40 (95% CI -0.28 to 1.06), with no significant difference
(Gupta 1995). Days of work lost per crisis were 3.4 in the zinc
group and 4.9 in the control group. Although there is a significant
reduction in the number of work days lost in the zinc group, MD
-1.50 (95% CI -2.24 to -0.76), on average hospital stay was longer
in this group.
4. Other sickle-related events

In the Phase II senicapoc study, there was one episode of staphylococcal sepsis in the low-dose senicapoc group and one urinary tract
infection in the high-dose senicapoc group (Ataga 2008). There
was one report of muscle strain in the high-dose senicapoc group
and once case of bronchitis in the placebo group (Ataga 2008).
In the Phase III senicapoc study there was no significant difference in other sickle cell-related events (pneumonia, asthma, fever,
catheter-related infections) between the senicapoc and the placebo
groups (Ataga 2011).
In the zinc study, there were 108 episodes of infection reported
in the intervention group compared to 204 in the control group
(Gupta 1995).
5. Adverse drug reactions

In the Phase II senicapoc study three participants discontinued the
study due to adverse events (Ataga 2008). One of the participants

Zinc deficiency in sickle cell disease has been shown in observational studies to correlate with disease severity (Gupta 1987;
Karayalcin 1974). Laboratory studies have shown that zinc can improve the sickle cell membrane status and antagonise intracellular
calcium, and could therefore affect red cell dehydration (Bennekou
2001). The Gupta study included in this review showed a significant reduction in the number of sickle-related events in one and
a half years of use in people treated with zinc sulphate (Gupta
1995). However, lack of data in the publication makes it difficult
to analyse the effect on other outcomes, on painful crisis frequency
in particular. In addition, changes to hematological indices, which
could be used as biomarkers of RBC sickling, were inconclusive.
Further research is required to evaluate the effect of zinc on the
basic mechanisms of sickle cell disease. Previous studies using zinc
also suggest a benefit for other problems in sickle cell disease, including leg ulcers (Serjeant 1970), growth (Zemel 2001), infection (Prasad 1999) and androgen deficiency in male participants
(Prasad 1981). However, these studies were not included in the review since they do not consider prevention of vaso-occlusive crises.
Senicapoc (ICA-17043) is a selective and potent blocker of the
Gardos channel in the RBC (Stocker 2003). The effect of this
drug on the markers of hemolysis and hemoglobin level was evaluated in a 12-week, Phase II randomized double-blind study in
people with sickle cell disease (Ataga 2008). The findings of this
study suggested an increase in the lifespan of the sickle red cells,
but there was no difference in the incidence of painful crises. A
subsequent Phase III study was terminated early due to the lack
of improvement in the vaso-occlusive pain crisis in people with
sickle cell disease (Ataga 2011).
A number of other studies did not satisfy the inclusion criteria,
but are still relevant to this review. Cetiedil citrate is believed to act
at the Gardos channel, antagonising the calcium-mediated potassium efflux from RBCs, thus affecting red cell hydration and preventing sickling. In two randomized controlled trials investigating
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this treatment of sickle pain crises, both found it to limit the duration of a pain crisis and reduce the number of sites of pain compared to placebo (Benjamin 1986; Cabannes 1983). No studies
have tested its use in preventing sickle crises.
Piracetam improves red cell rheology; however, the exact mechanism of this on the red cell membrane is unclear. It was initially
believed to inhibit the Gardos channel, but later studies disproved
this theory (Stone 1988; Stuart 1992). It has been shown in one
randomized controlled trial to decrease the number of pain crises
(Piracetam Study 1998) and in another to have no effect in preventing pain crises (Alvim 2005). For further information, please
see the relevant Cochrane Review (Al Hajeri 2007).
Magnesium is known to inhibit the potassium-chlorine ion pump,
and observational studies have shown benefits in sickle cell disease.
Sodium cromoglicolate can stabilise erythrocyte membranes by
blocking chlorine or calcium channels. In an ex vivo study, two
groups of nine children were given sodium cromoglicolate either
by the nasal route or inhalation (Toppet 2000). The percentage
of sickled cells in the blood of all children significantly decreased,
regardless of which group they were assigned to. Further studies
are now needed to test the clinical benefit of this agent.
Diltiazem also proved useful in a pilot study which measured sickle
pain intensity and duration and various hematological parameters
(Rubio 1992). It is a calcium channel blocker and may impact on
red cell hydration.
It was been hypothesised that hydroxyurea may increase intrinsic
levels of nitric oxide, and this may affect red cell hydration. Effectiveness of hydroxyurea is considered in a different Cochrane
Review (Jones 2001).
Zinc sulphate appears to be of benefit to people with sickle cell
disease (Gupta 1995).
However, further research in the form of large well-designed randomized controlled trials is required to fully elucidate the true
value in sickle cell disease of drugs which aim to prevent red cell
dehydration.

AUTHORS’ CONCLUSIONS
Implications for practice
There is evidence that zinc sulphate is associated with a reduction
in pain crises, and also with reductions in other sickle cell-related
crises. This was despite the treatment not being associated with an
improvement in any of the hematological outcomes. While these
results are encouraging, widespread introduction of this agent in
the management of people with sickle cell disease is not indicated
at present.
Senicapoc clearly improves the red cell survival in a dose-dependent manner. But the improvement in the laboratory measures did
not translate into clinical benefits. There was no reduction in the
incidence of sickle cell crises with the use of senicapoc. Therefore,
currently this drug cannot be used in clinical practice for the prevention of vaso-occlusive crises.

Implications for research
More studies are needed to evaluate the effect of zinc sulphate
and of piracetam on the basic mechanisms of sickle cell disease.
Further multicenter randomized controlled trials of zinc sulphate
in people with sickle cell disease should be conducted. To investigate whether the findings previously reported are consistent and
sustained, these future studies should be larger and longer term
than the one reported in this review. Senicapoc improved red cell
survival and decreased hemolysis. Further studies are needed to
ascertain if this drug will be beneficial in some of the other complications of sickle cell disease such as pulmonary hypertension.
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]
Ataga 2008
Methods

Phase II, randomized, double-blind, placebo-controlled study. There was a screening
phase and a 12-week treatment phase

Participants

Ninety sickle cell patients were recruited at nineteen medical centers in the USA. The
patients were adults aged between 18 and 60 years with at least one episode of sickle cell
related painful crisis four weeks prior to the study screening

Interventions

Patients were randomized to either:
1. high-dose senicapoc: a single 150 mg senicapoc loading dose followed by 10 mg daily
maintenance dose;
2. low-dose senicapoc: a single 100 mg senicapoc loading dose followed by 6 mg daily
maintenance dose; or
3. placebo.

Outcomes

Efficacy, safety, pharmacokinetic, and pharmacodynamic measures were obtained on day
1 of study, end of week 1 and every two weeks until the end of treatment phase

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Centralized randomization protocol using
an integrated voice response system

Allocation concealment (selection bias)

Allocation concealment was not reported.

Unclear risk

Blinding (performance bias and detection Low risk
bias)
Participants

The participants were blinded.

Blinding (performance bias and detection Low risk
bias)
Clinicians

The treating physicians were blinded.

Blinding (performance bias and detection Low risk
bias)
Outcome assessors

The review committee was blinded.

Incomplete outcome data (attrition bias)
All outcomes

Modified intent to treat population was
used for analysis. Two participants dropped
out prior to the first efficacy analysis. A total of ten participants did not complete the

Low risk
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Ataga 2008

(Continued)

study; full reasons for this were given in the
published paper
Selective reporting (reporting bias)

Low risk

All outcomes stated in ’Methods’ section
reported in ’Results’

Other bias

Low risk

No significant differences in the baseline
characteristics of the study participants

Ataga 2011
Methods

Phase III randomized, double-blind, placebo-controlled, parallel group study. There was
a screening phase, a 52-week treatment phase, and a follow-up evaluation 8 weeks after
the end of the study

Participants

297 patients were recruited from 75 centers in the USA, Jamaica, Brazil, France, Trinidad
and the United Kingdom. Participants aged between 16 and 65 years and had at least 2
episodes of painful crisis within the preceding 12 months that required medical attention
were included. Patients on hydroxyurea in preceding 12 months were required to be on
a stable dose of the drug prior to inclusion in the study

Interventions

Participants were randomized to receive (in a 1:1 fashion):
1. senicapoc (loading dose of 20 mg twice daily for 4 days followed by 10 mg daily); or
2. placebo

Outcomes

The primary end point was the frequency of sickle cell pain crises. TIme to the first
second and third acute painful crises was a secondary end point of the study (Ataga 2011)
. The effect of the drug on markers of hemolysis, hemoglobin, hematocrit, reticulocyte
count, red blood cell count and dense erythrocytes was also measured. Quality of life
measures were also included

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Centralized randomization protocol using
an integrated voice response system

Allocation concealment (selection bias)

Allocation concealment was not reported.

Unclear risk

Blinding (performance bias and detection Low risk
bias)
Participants
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Ataga 2011

(Continued)

Blinding (performance bias and detection Low risk
bias)
Clinicians

The treating physicians were blinded.

Blinding (performance bias and detection Low risk
bias)
Outcome assessors

The review committee was blinded.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Modified intent to treat population was
used for analysis. The study had to be terminated prematurely because it was unlikely to meet the primary end point

Selective reporting (reporting bias)

Low risk

All outcomes stated in ’Methods’ section
reported in ’Results’

Other bias

Low risk

No significant differences in the baseline
characteristics of the study participants

Gupta 1995
Methods

Double-blind, placebo-controlled, randomized controlled trial

Participants

145 participants from India with SS disease, aged over 5 years. 15 participants were lost
to follow up

Interventions

Zinc (oral 220 mg tds) or placebo (identical in appearance). Participants were seen weekly,
follow up was for 1.5 years and the data were analysed at the end of the follow-up period

Outcomes

Sickle related crises: vaso-occlusive; mixed; hemolytic; sequestration; and aplastic. Days
in hospital and working days lost

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

New Castle software was used to generate
randomization.

Allocation concealment (selection bias)

Allocation concealment was not reported.

Unclear risk

Blinding (performance bias and detection Low risk
bias)
Participants
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Gupta 1995

(Continued)

Blinding (performance bias and detection Low risk
bias)
Clinicians

The treating physicians were blinded.

Blinding (performance bias and detection Unclear risk
bias)
Outcome assessors

Not discussed.

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Fifteen, of the 145 participants recruited,
dropped out or were lost to follow up, and
these are not accounted for in the study
publication

Selective reporting (reporting bias)

Low risk

All outcomes stated in ’Methods’ section
reported in ’Results’

Other bias

Unclear risk

Little information was given regarding
baseline characteristics, including disease
severity and medical history of participants,
making it difficult to ascertain if the groups
were sufficiently similar at the start of the
study

IV: intravenous
SCD: sickle cell disease
SS: sickle cell anemia
tds: three times daily

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Adadevoh 1973

RCT of megestrol acetate. There is no good recent evidence to suggest that sex hormones prevent dehydration
of the sickle red cells

Adams-Graves 1997

Trial of poloxamer 188 - inappropriate mechanism of action for inclusion in this review

Akinsulie 2005

RCT of Cajanus cajan. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red cell membrane

Al-Jam’a 1999

Trial of isoxsurpine in treatment of sickle cell crises - rather than prevention

Alvim 2005

RCT of piracetam. There is a lack of evidence that the anti-sickling effect of the drug is due to a reduction
in water loss through the cell membrane
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(Continued)

Ataga 2002

Pharmacokinetic study of ICA 17043, with no measure of clinical outcomes of interest

Ayra 1996

RCT of tucaresol. Prevents sickling by shifting the oxygen affinity, not through red cell dehydration

Bartolucci 2009

RCT of ketoprofen for treatment of, rather than prevention of, vaso-occlusive crises.Not a study of a drug
involved in the prevention of red blood cell dehydration

Beatty 2007

Not a study of a drug involved in the prevention of red blood cell dehydration and vaso-occlusive crisis

Benjamin 1986

RCT of cetiedil citrate. Used in treatment rather than prevention of crises

Billet 1989

RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red cell membrane

Cabannes 1983

RCT of cetiedil citrate. Used in treatment rather than prevention of crises

Cabannes 1984

RCT of ticlopidine. Mainly an inhibitor of platelet action, rather than anti-dehydration

De Abood 1997

RCT of Depo-Provera and Microgynon. There is no good evidence to suggest that sex hormones prevent
dehydration of the sickle red cells

De Ceulaer 1982

RCT of medroxyprogesterone acetate. There is no good recent evidence to suggest that sex hormones prevent
dehydration of the sickle red cells

De Ceulaer 1990

RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red cell membrane

Gail 1982

RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the
sickle red cells

Gladwin 2011

Not a study of a drug involved in the prevention of red blood cell dehydration

Godeau 2003

RCT of ketoprofen for treatment, rather than prevention, of vaso-occlusive crises

Isaacs 1971

RCT of steroids. There is no good recent evidence to suggest that sex hormones prevent dehydration of the
sickle red cells

Jacobson 1997

Risk analysis using data from a previous RCT, in which morphine was administered in treatment, rather
than prevention, of acute chest syndrome

Lonsdorfer 1984

RCT of ticlopidine. Mainly an inhibitor of platelet action, rather than anti-dehydration

Mahmood 1969

RCT of a phenothiazine. Used in treatment rather than prevention of crises

Manion 2001

Pharmacokinetic study of aspartame, with no measure of outcomes of interest
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(Continued)

Manrique 1987

RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red cell membrane

Orringer 1991

RCT of 12C79, which prevents sickling primarily by increasing oxygen affinity, with possible secondary
effects on the potassium-chloride co-transport channels in the red cell membrane

Osamo 1981

Trial of aspirin. There is no evidence that any anti-sickling action is due to a reduction in dehydration of
the sickle red cells

Oski 1968

Study not randomized, looks at promazine chloride.

Oyewo 1987

Study of diflusinal, anti-sickling effects not due to red cell dehydration

Pace 2003

Phase II RCT of N-Acetylcysteine for prevention of sickle cell related vaso-occlusion and formation of dense
cells. There is insufficient evidence that N-Acetylcysteine acts via red cell dehydration to include this study
in the review

Pichard 1987

RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the cell membrane

Piracetam Study 1998

RCT of piracetam. There is a lack of evidence that the anti-sickling effect of the drug is due to a reduction
in water loss through the cell membrane

Poflee 1991

RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the cell membrane

Qari 2007

RCT of tinzaparin. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red cell membrane

Rubio 1992

Pharmacokinetic study of diltiazem, with no measure of outcomes of interest

Semple 1984

RCT of ticlopidine. Mainly an inhibitor of platelet action, rather than anti-dehydration

Silva-Pinto 2007

Study of hydroxyurea, no measure of clinical outcomes of interest

Teuscher 1988

RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the cell membrane

Toppet 2000

Non-randomized ex-vivo study of sodium cromoglicate, an anti-sickling agent, majority of patients also
taking hydroxyurea

Urea Trial 1974

RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the
sickle red cells

Urea Trial 2 1974

RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the
sickle red cells
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Urea Trial 3 1974

RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the
sickle red cells

Uzun 2010

Study of tramadol or meperidine for treatment of, rather than prevention of, vaso-occlusive crises. Not a
study of a drug involved in the prevention if red blood cell dehydration

Wallen 2007

Not a study of a drug involved in the prevention of red blood cell dehydration

Wambebe 2001

RCT of Niprisan, a naturally occurring compound. There is no evidence that any anti-sickling action is due
to a reduction in dehydration of red cells

Weiner 2002

Study of nitric oxide. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red cell membrane

Wynn 2007

Study of hydroxyurea, no measure of clinical outcomes of interest

Zago 1984

Trial of aspirin. There is no evidence that any anti-sickling action is due to a reduction in dehydration of
the sickle red cells

RCT: randomized controlled trial
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DATA AND ANALYSES

Comparison 1. Anti-sickling drug versus placebo

No. of
studies

Outcome or subgroup title
1 Mortality
2 Number of other serious
sickle-related complications
2.1 Overall
3 Quality of life measures
3.1 Hospital stay per crisis
(days)
3.2 Loss of work days/crisis

No. of
participants

Statistical method

Effect size

1
1

Odds Ratio (M-H, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)

Totals not selected
Totals not selected

1
1
1

Mean Difference (IV, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]
Totals not selected
0.0 [0.0, 0.0]

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Analysis 1.1. Comparison 1 Anti-sickling drug versus placebo, Outcome 1 Mortality.
Review:

Drugs for preventing red blood cell dehydration in people with sickle cell disease

Comparison: 1 Anti-sickling drug versus placebo
Outcome: 1 Mortality

Study or subgroup

Gupta 1995

Anti-sickling drug

Placebo

Odds Ratio

Odds Ratio

n/N

n/N

M-H,Fixed,95% CI

M-H,Fixed,95% CI

0/65

0/65

0.0 [ 0.0, 0.0 ]

0.1 0.2

0.5

Favours drug tmt
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Analysis 1.2. Comparison 1 Anti-sickling drug versus placebo, Outcome 2 Number of other serious sicklerelated complications.
Review:
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Comparison: 1 Anti-sickling drug versus placebo
Outcome: 2 Number of other serious sickle-related complications

Study or subgroup

Anti-sickling drug

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

65

2.46 (1.04)

65

5.29 (2.58)

Mean
Difference

IV,Fixed,95% CI

IV,Fixed,95% CI

1 Overall
Gupta 1995

-2.83 [ -3.51, -2.15 ]

-4

-2

0

Favours drug tmt

2

4

Favours placebo

Analysis 1.3. Comparison 1 Anti-sickling drug versus placebo, Outcome 3 Quality of life measures.
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Comparison: 1 Anti-sickling drug versus placebo
Outcome: 3 Quality of life measures

Study or subgroup

Anti-sickling drug

Mean
Difference

Placebo

Mean
Difference

N

Mean(SD)

N

Mean(SD)

IV,Fixed,95% CI

IV,Fixed,95% CI

65

4.3 (2.2)

65

3.9 (1.6)

0.40 [ -0.26, 1.06 ]

65

3.4 (2.18)

65

4.9 (2.1)

-1.50 [ -2.24, -0.76 ]

1 Hospital stay per crisis (days)
Gupta 1995
2 Loss of work days/crisis
Gupta 1995

-4

-2

Favours drug tmt
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WHAT’S NEW
Last assessed as up-to-date: 19 April 2012.

Date

Event

Description

19 April 2012

New citation required but conclusions have not changed A new study has been included in the review but did not
lead to a change in conclusions (Ataga 2011).

19 April 2012

New search has been performed

A search of the Group’s Haemoglobinopathies Trials Register identified 34 references of which one has been listed
as an included study (Ataga 2011) and three as excluded
studies (Bartolucci 2009; Gladwin 2011; Uzun 2010).

HISTORY
Protocol first published: Issue 1, 2002
Review first published: Issue 4, 2002

Date

Event

Description

20 September 2010

Amended

Contact details updated.

11 November 2009

New citation required but conclusions have not A new lead author (SN) has updated this review with
changed
the existing co-author (SB)

11 November 2009

New search has been performed

A search of the Group’s Trials Register identified eight
new references which were potentially eligible for inclusion in this review
One new study was included in the review (Ataga
2008).
Seven of these have been excluded; four references
were additional references to already excluded studies
(Beatty 2007; Qari 2007; Weiner 2002; Wynn 2007)
; and three were references to new studies (Akinsulie
2005; Silva-Pinto 2007; Wallen 2007).
Through personal communication, we have details of a
Phase III trial for which publication is pending (Ballas
2009). Full details will be included in a future update

4 September 2008

Amended

Converted to new review format.

19 July 2007

New citation required and conclusions have changed

Substantive amendment.
A new review team has updated this review. Dr Priya
C. Singh is now lead author with Dr Samir K. Ballas
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(Continued)

as co-author.
The former lead author, Ceri Hirst (née Riddington)
, and former co-author Dr Lucia de Franceschi are no
longer active authors on the review.
One trial previously included in this review has been
removed (Piracetam Study 1998). The piracetam trial
was excluded since the current authors believe there is
insufficient evidence that it acts primarily via the red
cell membrane to improve red cell rheology.
The search of the Group’s Haemoglobinopathies Trials Register in November 2006 identified trials possibly eligible for inclusion. Two references were to already excluded studies and these references have been
added to the appropriate study IDs (Adams-Graves
1997; Orringer 1991). One reference has been added
to Excluded studies (Alvim 2005).
1 June 2004

New search has been performed

The search of the Group’s trials register identified eight
new references, however, none were found to be eligible for inclusion in the review
Five references to three newly identified studies have
been excluded. Details of these studies can be found
in the Excluded studies section of the review (AdamsGraves 1997; Al-Jam’a 1999; Godeau 2003; Jacobson
1997; Pace 2003).
Three references identified were to two already excluded studies (Ataga 2002; Wambebe 2001). These
additional references have been added to the appropriate study IDs

1 July 2003

New search has been performed

Five new studies have been identified for inclusion
within the Excluded studies section of this review

CONTRIBUTIONS OF AUTHORS
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Review from Issue 4, 2009
Dr Singh has stepped down from the review team and Dr Nagalla is now the lead author for this review. Together with Dr Ballas, Dr
Nagalla has updated this review and acts as guarantor for this and subsequent versions of the review.

Review from Issue 4, 2007
Dr Singh is now lead author and updated the review with Dr Samir Ballas (co-author). Dr Singh acts as guarantor of the review. Dr
Singh reviewed the current literature on piracetam and revised the manuscript with advice from Dr Ballas.
Drs Hirst and de Franceschi have stepped down as active authors on this review.

Review up to Issue 3, 2007
The review was conceived by the Cochrane Cystic Fibrosis and Genetic Disorders Group and designed by Dr Hirst (née Riddington).
Dr Hirst and the Cochrane Cystic Fibrosis and Genetic Disorders Group conducted searches for relevant studies.
Dr Hirst and Dr de Franceschi screened, appraised and abstracted data for the review. Additional information from authors was sought
by Dr Hirst were necessary.
Data entry was performed by Dr Hirst and interpreted by Dr Hirst with advice from the Cochrane Cystic Fibrosis and Genetic Disorders
Group.
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